ReviewSeminars in immunology2010
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
Review in Seminars in immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03450044 (Immunogenicity and Safety of Autologous Dendritic Cells in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenicity and Safety of Autologous Dendritic Cells in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases.Annals of surgical oncology · 2021Trial
- Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- The Biology of Dendritic Cells: In Health and Disease.Advances in experimental medicine and biology · 2025Review
- Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform.Cellular & molecular immunology · 2024Article
- Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy.Molecular biology reports · 2024Review
- Generation of high cross-presentation ability human dendritic cells by combination of interleukin 4, interferon β and GM-CSF.Central-European journal of immunology · 2022Article
- Antitumor activity of recombinant oncolytic vaccinia virus with human IL2.Open medicine (Warsaw, Poland) · 2022Article
- Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer.World journal of clinical oncology · 2021Review
- Monocytes complexed to platelets differentiate into functionally deficient dendritic cells.Journal of leukocyte biology · 2021Article
- Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.NPJ vaccines · 2021Article
- Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.Frontiers in oncology · 2021Review
- Review
- Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.Pharmaceutics · 2020Review
- Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers · 2019Review
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.Journal for immunotherapy of cancer · 2019Review
- Further clinical advancement of dendritic cell vaccination against ovarian cancer.Annals of research hospitals · 2018Article
- Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment.Genes & cancer · 2018Review
- Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.Frontiers in immunology · 2018Review
- Dendritic cell based vaccination strategy: an evolving paradigm.Journal of neuro-oncology · 2017Review
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncoimmunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Ex vivo generation and antigen loading of dendritic cells (DCs) from cancer patients helps to bypass the dysfunction of endogenous DCs. It also allows to control the process of DC maturation and to imprint in maturing DCs several functions essential for induction of effective forms of cancer immunity. Recent reports from several groups including ours demonstrate that distinct conditions of DC generation and maturation can prime DCs for preferential interaction with different (effector versus regulatory) subsets of immune cells. Moreover, differentially-generated DCs have been shown to imprint different effector mechanisms in CD4(+) and CD8(+) T cells (delivery of "signal three") and to induce their different homing properties (delivery of "signal four"). These developments allow for selective induction of tumor-specific T cells with desirable effector functions and tumor-relevant homing properties and to direct the desirable types of immune cells to tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.